BayPAP is a program designed to assist Malaysian patient who have been diagnosed and prescribed with Nexavar or Stivarga by their doctors. BayPAP is part of Bayer Healthcare’s initiative to provide drug assistance to Malaysian patients in helping them to continue their treatments for as long as it is medically required.
We are committed to process your application within 3 business days upon receiving all necessary forms and supporting documents via the portal.
We apologise that we are unable to provide further support to your treatment in this instance. Should there be changes in your income/insurance status, please let us know and we will review your application again.
Bayer has appointed Zuellig Pharma as the partner to administer the program on its behalf. This partnership is to ensure independence and transparent execution of the BayPAP.
Zuellig Pharma’s Role:
Apart from AE Reporting which is required by law, Zuellig Pharma will not share patient’s personal identifiable information with Bayer. Only program performance and aggregated data will be shared as part of the program service.